90
Participants
Start Date
July 15, 2022
Primary Completion Date
May 26, 2023
Study Completion Date
May 29, 2023
NL005 Middle Dose
Patients in this treatment group will receive NL005 for 0.5 ug/kg respective.Continuous administration for 7 days.
NL005 High Dose
Patients in this treatment group will receive NL005 for 1.5 ug/kg respective.Continuous administration for 7 days.
Placebo
30 subjects will be randomly assigned to the placebo for 7 days
Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing
Beijing Northland Biotech. Co., Ltd.
INDUSTRY